Ipamorelin Stacking Guide: Best Combinations & Protocols (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Stacking
Ipamorelin + CJC-1295 (no DAC) / Mod GRF 1-29
This is the most popular combination. The GHRH analog primes the pituitary while ipamorelin amplifies release, creating a synergistic effect that produces greater GH elevation than either peptide alone. Typical dosing involves equal amounts (e.g., 100 mcg of each) administered simultaneously. See the ipamorelin vs GHRP-6 guide for a comparison of the main GHRP options, or the CJC-1295 vs ipamorelin page for stacking context.
Ipamorelin + BPC-157
For injury recovery and healing applications, some users combine ipamorelin's systemic regenerative effects with BPC-157's localized tissue repair properties.
Ipamorelin + Tesamorelin
This combination pairs ipamorelin with tesamorelin, an FDA-approved GHRH analog, potentially offering enhanced fat reduction, particularly in the abdominal region. See the tesamorelin vs ipamorelin comparison for a deeper look at how these two peptides differ.
When stacking, users typically maintain standard ipamorelin dosing while adding complementary peptides according to their individual protocols.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561.
Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66.
Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231.
Ghigo E, et al. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
World Anti-Doping Agency. Prohibited List.
Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
U.S. Food and Drug Administration.
Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine. 2008;149(9):601-611.